Dr. Parekh on Using Genomics in Multiple Myeloma Treatment

Samir Parekh, MBBS
Published: Thursday, Sep 19, 2019



Samir Parekh, MBBS, associate professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai Hospital, discusses using genomics to treat patients with multiple myeloma.

Physicians are using genomics to identify new drivers to understand myeloma better, find treatment for patients, and find the impact of genomics of the tumor on the tumor microenvironment, explains Parekh. For prognosis, physicians are looking at RNA expression patterns to build a new map of myeloma and find parts of the map associated with poor-risk myeloma, says Parekh.

For immunology, neoantigens can be used to treat patients and track their disease, as these tumor mutations elicit responses that can be the most direct measure of the immunotherapies that are being used in myeloma, including immunomodulatory agents and monoclonal antibodies, concludes Parekh.
SELECTED
LANGUAGE


Samir Parekh, MBBS, associate professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai Hospital, discusses using genomics to treat patients with multiple myeloma.

Physicians are using genomics to identify new drivers to understand myeloma better, find treatment for patients, and find the impact of genomics of the tumor on the tumor microenvironment, explains Parekh. For prognosis, physicians are looking at RNA expression patterns to build a new map of myeloma and find parts of the map associated with poor-risk myeloma, says Parekh.

For immunology, neoantigens can be used to treat patients and track their disease, as these tumor mutations elicit responses that can be the most direct measure of the immunotherapies that are being used in myeloma, including immunomodulatory agents and monoclonal antibodies, concludes Parekh.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x